background. A number of drugs have been used to prevent aging changes. However, studies of oral isotretinoin, the commonly used acne drug, as an antiaging drug are lacking. objective. To determine improvement in cutaneous aging utilizing oral isotretinoin combined with different procedures of facial rejuvenation. methods. Sixty patients ranging in age from 35 to 65 years, in whom additional modalities of rejuvenation were also used, were randomly assigned to receive treatment with oral isotretinoin (10-20 mg three times a week for 2 months, group A). Their results were compared with 60 patients who had undergone the same surgical procedures but with no oral isotretinoin (group B).
IT IS VERY important to recognize that facial aging is a process with multiple components. [1] [2] [3] [4] We divide it into three different components, each one with its own solution. This division is based on the level of the tissue in which the drug or device is placed and is acting, as well as the form in which it is administered. 5 The three components are the superficial component-peeling with resorcinol or ␣ -hydroxy acid (AHA), sunscreens, moisturizers, dermal fillers (collagen, hyaluronic acid, polymethyl methacrilate), topical tretinoin, and laser; 5-7 the deep component-Goretex, botox, fat transfer, and lifting, [5] [6] [7] [8] and the systemic component-oral isotretinoin. 5 In 1994 we reported our favorable experience using isotretinoin in the treatment of acne vulgaris. 9 Our goal now is to show the good response obtained over several years using isotretinoin for the improvement of cutaneous aging. The addition of oral isotretinoin as a treatment for the systemic component is a very important part of this program, which makes it different. With the experience obtained using isotretinoin in the treatment of acne, we recognize its beneficial effects and low occurrence of side effects. [9] [10] [11] 
Materials and Methods
Sixty patients were randomly assigned to receive oral isotretinoin for rejuvenation purposes. In all of them, additional modalities of rejuvenation were also used (group A). Their ages ranged from 35 to 65 years. There were 42 women and 18 men. All the patients were Hispanic. A careful personal and family history regarding hypercholesterolemia and hepatic or renal problems was obtained from each patient.
Blood work was performed before beginning treatment and 1 month later consisting of fasting blood sugar, cholesterol, triglycerides, transaminases, and creatinine. Since the medication was used for rejuvenation purposes, it was administered in small doses, 10-20 mg three times a week, according to body weight, over periods no longer than 2 months. In women we were very careful that they were postmenopausal, had a hysterectomy, or were using an effective birth control method. All the patients were informed about the study and a consent form was signed by each. They were evaluated for a minimum of 6 months after the end of the study.
Photographs were taken at the beginning and end of the treatment, and were compared with 60 patients who had undergone the same surgical procedures, but with no oral isotretinoin (group B). Parameters assessed included improvement in the general signs of aging (wrinkles, discoloration, thickness, oiliness, and size of the follicular pores) and general improvement of the skin. All of these parameters were quantitated on a scale from ϩ to ϩϩϩ by two different medical observers and by the patient. Differences in the quantitation were submitted to statistical analysis (Wilcoxon test). Side effects were also carefully checked by the physician and by the patient.
The types of surgical procedures performed in patients of group A are shown in Table 1 . Patients in group B underwent similar or equivalent procedures, but with no oral isotretinoin.
Results
All the patients in group A noted improvement in their wrinkles, thickness and color of skin, size of pores, as well as a general improvement in the aspect of the skin. The skin became very smooth and lighter in color. Skin tone and elasticity improved. Improvement was seen in frontal wrinkling, glabellar lines, crow's feet, circumoral and neck lines, and a reduction in pigmented lesions (lentigines, ephelides) and mottled hyperpigmentation was noted. All the parameters assessed were significantly improved in the skin of group A patients as compared with group B (Figures 1, 2) . The total number of crosses assigned to each parameter (wrinkles, discoloration, thickness, oiliness, size of follicular pores, and general appearance of the skin) were summed for group A and compared with that of group B. Differences were then submitted to the Wilcoxon range test. It was found that there was a statistically significant difference between both groups (Wilcoxon test, P Ͻ .01). The skin in the patients of group A appeared to be more elastic, softer, smoother, and lighter in color compared with patients in group B. The degree of satisfaction experienced by patients in group A was also better than in group B, in which only surgical procedures were performed but no the oral isotretinoin was given. Using minimal amounts of this drug, the side effects were nonexistent or negligible, limited sometimes to minimal dryness of the lips (less than 10% of cases).
Discussion
We have been using oral isotretinoin since 1982. While treating patients, we observed an improvement in not only their acne, but also in their skin in general. 9 The skin became softer, lighter, and rosy pink in color; in the words of the patients, "just like the skin of a baby." This observation led us to believe that isotretinoin was not only effective in acne, but also in aging. When we started using isotretinoin for rejuvenation purposes in 1992, we found improvement in both intrinsic and photoaged skin. [9] [10] [11] Systemically, isotretinoin is converted to tretinoin. Tretinoin improves the appearance of aged skin by reducing in wrinkles and pigmented lesions (lentigines, ephelides). [12] [13] [14] [15] [16] [17] [18] The total cumulative dose of isotretinoin in acne therapy has been established as 120 mg/kg per series. 19 Low doses of this drug can be used for the treatment of aging, depending on the weight, the age, and the clinical response of the patient. We used 10-20 mg of oral isotretinoin three times a week over 2 months. Even this low dose has been found to be effective for the treatment of aging skin. 5 If the aging changes are severe, therapy can be repeated after stopping for several months. The effect of the drug probably lingers for several months or years on the skin. [19] [20] [21] [22] [23] [24] The skin becomes more pliable, softer, smoother, and lighter in color. However, patients should be advised that the skin will be drier, slightly scaly, and in some cases reddened after the use of the drug, but after 2-3 weeks the irritation diminishes as the skin develops a tolerance to the drug. [19] [20] [21] [22] [23] [24] Patient monitoring and care are the same as while using isotretinoin for acne cases. Monitoring of blood lipids and transaminases is done at monthly intervals. In women, strict contraception is required during therapy and for at least 1 month afterwards. Nasal and lip moisturizers and skin emollients are regularly used during therapy to combat the dryness caused by the drug. [19] [20] [21] [22] [23] [24] Isotretinoin and tretinoin are interconvertable in vivo; 25 20-30% of a dose of isotretinoin is metabolized by this route. With repeated administration, the major metabolite 4-oxoisotretinoin accumulates in the blood. Excretion of metabolites and the parent compound in the bile occurs after conjugation with glucoronic acid and taurine. 25 Tretinoin is metabolized rapidly in the liver into bile and excreted in urine and feces. 25 The half-life of isotretinoin ranges from 6 to 36 hours in plasma. With repeated administration, a steady-state concentration is reached in 5-7 days. Several of its metabolites are cleared from the plasma rather slowly. 25 The clinical usefulness of topical isotretinoin is limited by its inability to pass the stratum corneum. 26 Cyclodextrins are penetration enhancers that have recently proved useful, enhancing the dermal and transdermal delivery of acitretin, tretinoin, betamethasone, hydroquinones, and various other topical drugs. 27 However, studies on the use of topical isotretinoin and cyclodextrins are lacking. It is possible that topical isotretinoin with a penetration enhancer such as cyclodextrin might prove to be useful in intrinsic and photoaged skin. 27 
Conclusion
Combining all of the above mentioned elements in the treatment of the superficial, deep, and systemic components of facial aging gives very nice results. Utilization of different procedures with oral isotretinoin allowed us to improve the effects of cutaneous aging. The use of low doses of oral isotretinoin seems to be a safe and simple addition to well-known surgical procedures in the fight against aging.
